Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

References

• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Nathan DM Cleary PA Backlund JY Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 2005 353 25 2643 2653 16371630
   PubMed Web of Science ®Google Scholar
• Gaede P Vedel P Larsen N Jensen GV Parving HH Pedersen O Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 2003 348 5 383 393 12556541
   PubMed Web of Science ®Google Scholar
• Cheung BM Ong KL Cherny SS Sham PC Tso AW Lam KS Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006 Am J Med 2009 122 5 443 453 19375554
   PubMed Web of Science ®Google Scholar
• Eeg-Olofsson K Cederholm J Nilsson PM Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients Diabetologia 2009 52 1 65 73 18985314
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 1 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Bays H Mandarino L DeFronzo RA Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach J Clin Endocrinol Metab 2004 89 2 463 478 14764748
   PubMed Web of Science ®Google Scholar
• Anderson JW Konz EC Obesity and disease management: effects of weight loss on comorbid conditions Obes Res 2001 9 Suppl 4 326S 334S 11707561
   PubMedGoogle Scholar
• Handelsman Y Mechanick JI Blonde L American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan Endocr Pract 2011 17 Suppl 2 S1 S53
   PubMed Web of Science ®Google Scholar
• Cryer PE Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes Diabetologia 2002 45 7 937 948 12136392
   PubMed Web of Science ®Google Scholar
• Bays H Blonde L Rosenson R Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther 2006 4 6 871 895 17173503
   PubMedGoogle Scholar
• Marsenic O Glucose control by the kidney: an emerging target in diabetes Am J Kidney Dis 2009 53 5 875 883 19324482
   PubMed Web of Science ®Google Scholar
• Wright EM Hirayama BA Loo DF Active sugar transport in health and disease J Intern Med 2007 261 1 32 43 17222166
   PubMed Web of Science ®Google Scholar
• Vallon V Platt KA Cunard R SGLT2 mediates glucose reabsorption in the early proximal tubule J Am Soc Nephrol 2011 22 1 104 112 20616166
   PubMed Web of Science ®Google Scholar
• Wright EM Loo DD Hirayama BA Biology of human sodium glucose transporters Physiol Rev 2011 91 2 733 794 21527736
   PubMed Web of Science ®Google Scholar
• Grempler R Augustin R Froehner S Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter FEBS Lett 2011 586 3 248 253 22212718
   PubMed Web of Science ®Google Scholar
• Chen J William S Ho S Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members Diabetes Ther 2010 1 2 57 92 22127746
   PubMedGoogle Scholar
• Sabolic I Vrhovac I Balen ED Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences Am J Physiol Cell Physiol 2012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Santer R Calado J Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target Clin J Am Soc Nephrol 2010 5 1 133 141 19965550
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA DeFronzo RA Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus Endocr Pract 2008 14 6 782 790 18996802
   PubMedGoogle Scholar
• Bays H From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus Curr Med Res Opin 2009 25 3 671 681 19232040
   PubMed Web of Science ®Google Scholar
• Mogensen CE Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects Scand J Clin Lab Invest 1971 28 1 101 109 5093515
   PubMed Web of Science ®Google Scholar
• List JF Whaley JM Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans Kidney Int Suppl 2011 120 S20 S27 21358698
   PubMed Web of Science ®Google Scholar
• Petersen C Analyse des Phloridzins Annales Académie Science Française 1835 15 178 French
   Google Scholar
• Von Mering J Ueber kunstlichen diabetes Centralbl Med Wiss 1886 22 531 German
   Google Scholar
• Achard C Delamare V The bark of the apple root, phlorizin, reduces diabetic hyperglycemia Soc Medic Des Hopitaux 1899 379 393
   Google Scholar
• Chao EC Henry RR SGLT2 inhibition – a novel strategy for diabetes treatment Nat Rev Drug Discov 2010 9 7 551 559 20508640
   PubMed Web of Science ®Google Scholar
• Rossetti L Smith D Shulman GI Papachristou D DeFronzo RA Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats J Clin Invest 1987 79 5 1510 1515 3571496
   PubMed Web of Science ®Google Scholar
• Rossetti L Shulman GI Zawalich W DeFronzo RA Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats J Clin Invest 1987 80 4 1037 1044 3308956
   PubMed Web of Science ®Google Scholar
• Wells RG Pajor AM Kanai Y Turk E Wright EM Hediger MA Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter Am J Physiol 1992 263 3 Pt 2 F459 F465 1415574
   PubMed Web of Science ®Google Scholar
• Washburn WN Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents Expert Opin Ther Pat 2009 19 11 1485 1499 19852718
   PubMed Web of Science ®Google Scholar
• Obermeier M Yao M Khanna A In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans Drug Metab Dispos 2010 38 3 405 414 19996149
   PubMed Web of Science ®Google Scholar
• Han S Hagan DL Taylor JR Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats Diabetes 2008 57 6 1723 1729 18356408
   PubMed Web of Science ®Google Scholar
• Uveges A Hagan D Onorato J Dapagliflozin selectively inhibits human SGLT2 versus SGLT1, SMIT1, SGLT4, and SGLT6 Presented at the American Diabetes Association 71st Scientific Sessions June 24–28, 2011 San Diego, CA 2011 Poster P-987
   Google Scholar
• Poucher SM DeSchoolmeester J Ehenborn J Vernon W Clementz T Dapagliflozin selectivity for glucose transporters GLUT1, 2, and 4 Presented at the American Diabetes Association 71st Scientific Sessions June 24–28, 2011 San Diego, CA Poster P-1041
   Google Scholar
• Bristol Myers-Squibb, AstraZeneca US Food and Drug Administration Endocrinologic and Metabolic Advisory Committee background document: dapagliflozin, BMS-512148, NDA 202293 US Food and Drug Administration Available from: www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262993.htm Accessed July 20, 2011
   Google Scholar
• Devenny J Harvey S Rooney S The effect of dapagliflozin, a highly selective SGLT-2 inhibitor on body weight in diet-induced obese rats Obesity 2007 15 Suppl 19 A121
   Google Scholar
• Komoroski B Vachharajani N Feng Y Li L Kornhauser D Pfister M Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin Pharmacol Ther 2009 85 5 513 519 19129749
   PubMed Web of Science ®Google Scholar
• Salsali A Hruba V Ying L Reduction in postprandial glucose with dapagliflozin in type 2 diabetes [abstract] Diabetes 2011 60 A286:1104-P
   Web of Science ®Google Scholar
• Gerich JE Physiology of glucose homeostasis Diabetes Obes Metab 2000 2 6 345 350 11225963
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Liu X Pe Benito M LaCreta F Boulton DW Influence of renal function on dapagliflozin pharmacodynamics in patients with type 2 diabetes mellitus [abstract] Presented at the American Society of Nephrology November 8–13, 2011 Philadephia, PA 2011 TH-PO525
   Google Scholar
• Zinker B Ma X Liu H Chronic dapagliflozin treatment reduces elevated hepatic glucose production and enhances pancreatic insulin content in male ZDF rats [abstract] Diabetes 2011 60 A283: 1031-P
   Web of Science ®Google Scholar
• Ferrannini E Ramos SJ Salsali A Tang W List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial Diabetes Care 2010 33 2217 2224 20566676
   PubMed Web of Science ®Google Scholar
• Henry R Murray A Marmolejo MH Hennicken D Ptaszynska A List JF Dapagliflozin, metformin-XR, or both together as initial therapy for T2DM [abstract] Diabetes 2011 60 A84:307-OR
   Web of Science ®Google Scholar
• Bailey CJ Gross JL Pieters A Bastien A List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 2010 375 9733 2223 2233 20609968
   PubMed Web of Science ®Google Scholar
• Rosenstock J Vico M Wei L Salsali A List J Dapagliflozin added-on to pioglitazone reduces HbA1c and mitigates weight gain with low incidence of hypoglycemia in type 2 diabetes [abstract] Diabetes 2011 60 A270:986-P
   Web of Science ®Google Scholar
• Strojek K Yoon KH Hruba B Elze M Langkilde AM Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 2011 13 10 928 938 21672123
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Soler NG Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 2012 156 6 405 415 22431673
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Yadav M Iqbal N Mansfield TA List JF Long- term efficacy of dapagliflozin as add-on to metformin (MET) in T2DM inadequately controlled with MET alone [abstract] Diabetes 2011 60 A271:988-P
   Web of Science ®Google Scholar
• Woo V Tang W Salsali A List JF Long-term efficacy of dapagliflozin monotherapy in patients with type 2 diabetes mellitus [abstract] Presented at the International Diabetes Federation World Diabetes Congress December 4–8, 2011 Dubai, United Arab Emirates 2011 D-0991
   Google Scholar
• Nauck M Del Prato S Rohwedder K Theuerkauf A Langkilde A Parikh S Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results Presented at the American Diabetes Association 71st Scientific Sessions June 24–28, 2011 San Diego, CA 2011 40-LB
   Google Scholar
• Bavenholm PN Efendic S Postprandial hyperglycaemia and vascular damage – the benefits of acarbose Diab Vasc Dis Res 2006 3 2 72 79 17058626
   PubMedGoogle Scholar
• List JF Woo V Morales E Tang W Fiedorek FT Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 2009 32 4 650 657 19114612
   PubMed Web of Science ®Google Scholar
• Kohan DE Fioretto P List J Tang W Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract] J Am Soc Nephrol 2011 Suppl 22:TH-PO524 22021708
   PubMed Web of Science ®Google Scholar
• Zinker B Ma X Liu H Washburn W Whaley J Acute glucose fluxes following a single dose of dapagliflozin [abstract] Diabetes 2011 60 A273:995-P
   Web of Science ®Google Scholar
• Bailey CJ Gross JL Hennicken D Iqbal N Mansfield TA List JF Long-term efficacy of dapagliflozin as add-on to metformin in T2DM inadequately controlled with metformin alone Presented at the American Diabetes Association 71st Scientific Sessions June 24–28, 2011 San Diego, CA 2011 988–P
   Google Scholar
• Wilding JPH Woo V Soler NG Pahor A Sugg J Parikh S Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin [abstract] Diabetes 2010 59 LB7 Abstract 21-LB
   Web of Science ®Google Scholar
• Nauck MA Del Prato S Meier JJ Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 2011 34 9 2015 2022 21816980
   PubMed Web of Science ®Google Scholar
• Bolinder J Ljunggren O Kullberg J Effects of dapagliflozin on body weight, total fat mass and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 2012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Kahn SE The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes Diabetologia 2003 46 1 3 19 12637977
   PubMed Web of Science ®Google Scholar
• Macdonald FR Peel JE Jones HB The novel SGLT2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats Diabetes Obes Metab 2010 12 11 1004 1012 20880347
   PubMed Web of Science ®Google Scholar
• Jurczak MJ Lee HY Birkenfeld AL SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function Diabetes 2011 60 3 890 898 21357472
   PubMed Web of Science ®Google Scholar
• Salsali A Bastien A Mansfield T Ying L Ravichandran S List JF Dapagliflozin improves hyperglycemia and beta-cell function without increasing hypoglycemic episodes in patients with type 2 diabetes mellitus [abstract] Presented at the American Association of Clinical Endocrinologists April 13–17, 2011 San Diego, CA 2011 204
   Google Scholar
• Mudaliar S Henry R Boden G Changes in insulin sensitivity as measured by glucose disposal rate and acute insulin secretion with the sodium glucose co-transporter 2 inhibitor dapagliflozin Presented at the 47th Annual Meeting of the European Association for the Study of Diabetes September 12–16, 2011 Lisbon, Portugal 2011 Abstract 854
   Google Scholar
• Lang F Osmotic diuresis Ren Physiol 1987 10 3–4 160 173 3133729
   PubMedGoogle Scholar
• Heerspink HJ List J Boulton D Liu X Ying L deZeeuw D The SGLT2 inhibitor dapagliflozin, a proximal tubular diuretic with antihypertensive properties? Presented at the World Congress of Nephrology 2011 April 8–12, 2011 Vancouver, Canada 2011 Abstract SU183
   Google Scholar
• Wilding JP Norwood P T’joen C Bastien A List JF Fiedorek FT A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment Diabetes Care 2009 32 9 1656 1662 19528367
   PubMed Web of Science ®Google Scholar
• Wilcox CS Liu X Kasichayanula S Evaluation of interactions of dapagliflozin and bumetanide Presented at the American Society of Nephrology November 16–21, 2010 Denver, CO 2010
   Google Scholar
• Thomson SC Miracle C Rieg T Whaley J Vallon V Chronic SGLT2 blockade reduces proximal reabsorption and normalizes state of tubuloglomerular feedback activation in hyperfiltering diabetic rats [abstract] J Am Soc Nephrol 2009 20 734A:2723
   Google Scholar
• Kutina AV Zakharov VV Natochin YV Excretion of proteins by rat kidney during various types of diuresis Bull Exp Biol Med 2008 146 6 671 674 19513351
   PubMed Web of Science ®Google Scholar
• Lina BA Bos-Kuijpers MH Til HP Bar A Chronic toxicity and carcinogenicity study of erythritol in rats Regul Toxicol Pharmacol 1996 24 2 Pt 2 S264 S279 8933643
   PubMed Web of Science ®Google Scholar
• Parikh S Johnsson K Ptaszynska A Schmitz B Sugg J List JF Characterization of urinary tract infections in the setting of pharmacologically induced glucosuria [abstract] Diabetes 2011 60 A270:984-P
   Web of Science ®Google Scholar
• List JF Ley S Ptaszynska A Characterization of genital infections in the setting of pharmacologically-induced glucosuria [abstract] Diabetes 2011 60 A270:985-P
   Web of Science ®Google Scholar
• Campbell JM Fahey GCJr Wolf BW Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats J Nutr 1997 127 1 130 136 9040556
   PubMed Web of Science ®Google Scholar
• Kasahara M Maeda M Hayashi S Mori Y Abe T A missense mutation in the Na(+)/glucose cotransporter gene SGLT1 in a patient with congenital glucose-galactose malabsorption: normal trafficking but inactivation of the mutant protein Biochim Biophys Acta 2001 1536 2–3 141 147 11406349
   PubMed Web of Science ®Google Scholar
• Wright EM Genetic disorders of membrane transport. I. Gluocse galactose malabsorption Gastrointest Liver Physiol 1998 275 5 G879 G882
   Web of Science ®Google Scholar
• Zafar TA Weaver CM Zhao Y Martin BR Wastney ME Nondigestible oligosaccharides increase calcium absorption and suppress bone resorption in ovariectomized rats J Nutr 2004 134 2 399 402 14747679
   PubMed Web of Science ®Google Scholar
• Wilding JPH Woo V Soler NG Dapagliflozin in patients with type 2 diabetes poorly controlled on insulin therapy—efficacy of a novel insulin-independent treatment [abstract] Diabetes 2010 59 A21 A22 78-OR
   Web of Science ®Google Scholar
• Strojek K Hruba V Elze M Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and inadequate glycaemic control on glimepiride monotherapy Diabetologia 2010 53 S347:870-P
   Web of Science ®Google Scholar